@article {775,
	title = {Donor screening for human T-cell lymphotrophic virus 1/2: changing paradigms for changing testing capacity.},
	journal = {Am J Transplant},
	volume = {10},
	year = {2010},
	month = {Feb},
	pages = {207 - 13},
	abstract = {Organ Procurement and Transplant Network (OPTN) policy currently requires the testing of all potential organ donors for human T-cell lymphotrophic virus (HTLV)-1/2. Most Organ Procurement Organizations (OPO) use the Abbott HTLV-I/HTLV-II Enzyme Immunoassay (EIA). This assay will no longer be manufactured after December 31, 2009; the only commercially available FDA-licensed assay will be the Abbott PRISM HTLV-I/II assay which poses many challenges to OPO use for organ donor screening. As a result, screening donors for HTLV-1/2 in a timely manner pretransplant after December 31, 2009 will be challenging. The true incidence of HTLV-1 in United States (U.S.) organ donors is not well described but appears to be low ( approximately 0.03-0.5\%). HTLV-1 is associated with malignancy and neurological disease; HTLV-2 has not been convincingly associated with disease in humans. Donors that are HTLV-1/2 seropositive are infrequently used despite most results being either false positive or resulting from HTLV-2 infection. There is urgent need to encourage the development of assays, instruments and platforms optimized for organ donors that can be used to screen for transmissible disease in donors; these must have appropriate sensitivity and specificity to identify all infections while minimizing organ loss through false positive testing.},
	keywords = {Donor Selection, Human T-lymphotropic virus 1, Human T-lymphotropic virus 2, Humans, Immunoenzyme Techniques, Male, Sensitivity and Specificity, T-Lymphocytes, Tissue and Organ Procurement, Tissue Donors, United States, Viruses},
	issn = {1600-6143},
	doi = {AJT2867 [pii] 10.1111/j.1600-6143.2009.02867.x},
	author = {Kaul,D. R. and Taranto,S. and Alexander,C. and Covington,S. and Marvin,M. and Nowicki,M. and Orlowski,J. and Pancoska,C. and Pruett,T. L. and Ison,M. G. and Group,HTLV Donor Screening Advisory}
}
